Loading...
•
Sep 30, 2020
Theravance Q3 2020 Earnings Report
Theravance Biopharma reported financial results for the third quarter ending September 30, 2020.
Key Takeaways
Theravance Biopharma reported total revenue of $18.3 million for Q3 2020. The operating loss was $76.6 million, or $61.1 million excluding share-based compensation expense. The company's implied 35% share of net sales for YUPELRI during Q3 2020 was $13.0 million.
YUPELRI gained market share and delivered sales growth versus the second quarter.
YUPELRI achieved brand profitability for Theravance Biopharma in Q3 2020.
Clinical trial enrollment has seen a significant uptick.
Phase 3 results for ampreloxetine and TD-1473 Phase 2b results in ulcerative colitis and Phase 2 results in Crohn’s disease are expected in Q3 2021.
Theravance
Theravance
Theravance Revenue by Segment
Revenue by Segment
YUPELRI Collaboration Revenue
CapyFin.com Forward Guidance
Theravance Biopharma expects Phase 3 results for ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH) and for TD-1473 Phase 2b results in ulcerative colitis and Phase 2 results in Crohn’s disease in Q3 2021.